


# **EXHIBIT 71**

File Provided Natively



Highly Confidential

TEVA\_MDL\_A\_09643590



TEVA

Welcome to  
Teva Pharmaceutical  
Industries Ltd.


2017



TEVA

Teva at  
a glance



The Teva logo, consisting of the word "TEVA" in a stylized, blocky font with a blue-to-white gradient, is positioned in the upper left corner of the advertisement.A large, close-up photograph of a baby's face, showing the eyes, nose, and mouth. The baby has a joyful expression, with its mouth open in a smile. The image is slightly blurred, giving it a soft, intimate feel.

Teva is one of the leading pharma companies in the world, committed to increasing access to quality health solutions, with an unparalleled impact on patients and healthcare systems worldwide. This is how we enable people to live better, healthier lives







## Starting out in 1901 in Jerusalem

The company known today as Teva was established as a small wholesale drug business by Chaim Salomon, Moshe Levin and Yitschak Elstein. (They named it S.L.E after their names)





# We came a long way in the last century

Through mergers, acquisitions and organic growth, fueled by our commitment to patients and healthcare communities

---

The **leading** global generic company

---

A strong specialty medicines portfolio, as well as OTC & API

---

Commercial presence in 80 markets

---

**57,000** employees

---

2016 revenues: **\$21.9 billion**

TEVA



Headquartered in Israel

Distributing medicines in  
approximately 100 markets  
around the world

Our business is divided across  
the United States, Europe and  
Rest of the World (ROW).




TEVA

One of  
the most  
competitive  
operational  
networks in  
the industry



Manufactures

120 billion  
tablets &  
capsules annually



The world's largest 'medicine cabinet:'  
Generic, Specialty and OTC  
*1,800 molecules, 16,000 products*

Presentation Name | All Rights Reserved



Providing accessible quality  
medicines to 200 million patients  
around the world every day

---

1 in 6 prescriptions in the U.S.  
filled with a Teva medicine

---

1 in 8 prescription packs in the  
UK filled with a Teva medicine

---

1 in 5 prescriptions in Israel  
filled with a Teva medicine

Source: IMS





Saving billions for healthcare  
systems

---

Teva has saved the U.S. healthcare  
system

\$215 billion  
the past decade



Best in  
class R&D  
capabilities


26 R&D  
and clinical  
development  
sites

Pending  
**300** product  
registrations pending FDA  
approval

Leading with **100**  
pending first-to-file ANDAs in  
the U.S.


Over **600** pending  
product approvals in growth  
markets

Launches  
**1,000** generic  
launches globally in 2017



TEVA

## Our core therapeutic areas







## Central nervous system disorders

We are focused on improving the health of patients, mainly in multiple sclerosis (MS), movement disorders, neurodegenerative conditions, pain and migraine.

Copaxone™ Revolutionized treatment of relapsing-remitting multiple sclerosis (RRMS)

Azilect™ - A Leading treatment for the symptoms of Parkinson's Disease

Nuvigil™ - A Leading treatment for sleep disorders

Key research programs in Huntington disease (HD), migraine, pain and movement disorders

TEVA

**Copaxone®**

**The leading MS**

(multiple sclerosis)

**therapy in the world**

MS is the most common cause of neurological disability in young adults and affects more than 2.5 million people worldwide






TEVA

**The painful truth:**  
Pain is one of the most  
significant healthcare problems  
we face today

Impacting hundreds of millions of people,  
destroying quality of life, costing \$billions in  
treatment and lost productivity





TEVA

## Pain

We have a range of investigational,  
approved and marketed treatments

[REDACTED]  
Migraine

[REDACTED]  
Cancer pain

[REDACTED]  
Neuropathic pain

[REDACTED]  
Chronic pain


[REDACTED]  
A range of abuse deterrent  
opioids based on leading  
proprietary technology



## Respiratory

Helping the world breathe:  
Teva is ranked No. 4 in  
the world in Respiratory

Improving the lives of millions out  
of the 235 million people world-  
wide who are diagnosed as  
suffering from asthma, as well as  
from COPD and Nasal Rhinitis





We have a broad portfolio of in-line and pipeline products and solutions developed to meet the unique needs of patients across the spectrum of respiratory diseases

Asthma

COPD

Allergic Rhinitis


Optimizing respiratory therapies for patients through novel delivery systems

Targeted biologics





## Helping the world breathe: Spiromax<sup>®</sup>/RespiClick<sup>®</sup>



Breath-actuated dry powder  
inhaler

No "hand-breath coordination"  
during inhalation needed

Intuitive device, easy for patients  
to learn and use

Uses unique technology to deliver  
a consistent, effective and  
accurate dose



## Our leading specialty brands



## Building A Promising Specialty Pipeline

Phase 1	Phase 2	Phase 3	Registration	<div>25 products in phase 1 through submission</div>
TV-46139 (abuse deterrent) <i>Pain</i>	TV-45070 Topical <i>Neuropathic pain</i>	Fremanezumab (anti CGRP) <i>Chronic migraine (Global)</i>	Deutetrabenazine, SD-809 <i>Huntington Disease</i>	
TEV-90105 (abuse deterrent) <i>Pain</i>	Fasinumab ** <i>Chronic Lower Back Pain</i>	Fremanezumab (anti CGRP) <i>Episodic migraine (Global)</i>	Deutetrabenazine, SD-809 <i>Tardive dyskinesia</i>	
Deutetrabenazine, SD-809 <i>Tourette syndrome</i>	Laquinimod <i>Multiple sclerosis (primary progressive)</i>	Fremanezumab (anti CGRP) <i>Cluster Headache (Global)</i>	QVAR® (beclomethasone dipropionate BAI) <i>Asthma (U.S.)</i>	
Deulevodopa, SD-1077 <i>Parkinson's Disease</i>	Laquinimod <i>Huntington disease</i>	TV-46763 (abuse deterrent) <i>Pain</i>	Reslizumab* IV <i>Asthma (Global)</i>	
TV-46000 <i>Schizophrenia</i>	Pridopidine <i>Huntington disease</i>	Fasinumab ** <i>Osteoarthritis pain</i>	Fluticasone Propionate MDPI <i>Asthma (Growth markets)</i>	<div> <div>Migraine &amp; Pain</div>9 <div>Neurology &amp; neuropsychiatry</div>9 <div>Respiratory</div>5 <div>Biosimilars</div>2 </div>
		Laquinimod <i>Multiple sclerosis (relapsing remitting)</i>	Fluticasone Salmeterol MDPI <i>Asthma (Growth markets)</i>	
		Reslizumab* SC <i>Asthma (Global)</i>		
		CT-P10 *** <i>Biosimilar (Rituxan® U.S.)</i>		
		CT-P6 *** <i>Biosimilar (Herceptin® U.S.)</i>		

<sup>1</sup> Note: Pipeline is current as of Feb 1<sup>st</sup>, 2017. Phase 1 includes also projects designated for IND filing.  
\* Approved in the U.S under the trade name: CINQUAIR® \*\* In partnership with Regeneron \*\*\* In partnership with Celltrion






**We are developing  
unique patient-  
centric solutions  
in key areas**









We also have a unique Over The Counter partnerships with a world leader – P&G (Procter and Gamble)

Drawing on Teva's go-to-market expertise, experience in marketing branded medicines and P&G's marketing power



Expansion into new markets, such as South Asia, and fast-growing categories

Marketing more than 200 consumer healthcare brands in more than 70 countries





We are committed to  
the highest quality  
standards

Our R&D operations focus on  
creating quality medications  
through effective design

Our medicines are produced in  
state-of-the-art manufacturing  
facilities using the most  
advanced testing equipment

We supervise our suppliers'  
procedures to ensure that we are  
using the highest quality  
materials





## TEVA Israel Operations



**Kiryat Shmona** medical devices production  
**Netanya** API for pharmaceutical industries production, R&D  
**Kfar-Saba** R&D and Pharma  
**Petach-Tikva** company headquarters, R&D  
**Jerusalem** R&D and Pharma  
**Ashdod** hospital kits production  
**Rehovot** R&D  
**Neot Hovav** API for pharmaceutical industries production  
**Shoham** Teva IL marketing and distribution







Teva's investment  
in Israel  
Major contribution  
to Israel's economy,  
academia and the  
biotech industry

25% of Teva's sales originate in Israel manufacturing

Teva's academic royalty payments account for 12% of  
national high education budget


Over **7,000** employees, doubled since 2003

Over \$27B in exports over the past five years

Over \$4B investment in R&D and Innovation in the  
last decade



## Israel is an ecosystem of pharmaceutical solutions





## A strong biopharmaceutical cluster

### Presence of top global pharmaceutical companies:

 Global HQ R&D and manufacturing sites	 R&D and manufacturing sites	 Biotech incubator	 Biotech incubator	 Collaborations with Academia & clinical research arm	 Collaborations with Academia & clinical research arm	 Collaborations with Academia & clinical research arm
 Collaborations with Academia & clinical research arm	 Collaborations with Academia & clinical research arm	 Collaborations with Academia & clinical research arm	 Collaborations with Academia & clinical research arm	 Collaborations with Academia & clinical research arm	 Collaborations with Academia & clinical research arm	 Collaborations with Academia & clinical research arm
 Collaborations with Academia & clinical research arm	 Collaborations with Academia & clinical research arm	 Collaborations with Academia & clinical research arm	 Collaborations with Academia & clinical research arm	 Collaborations with Academia & clinical research arm	 Collaborations with Academia & clinical research arm	 Collaborations with Academia & clinical research arm






**Government :**

- Working closely with regulators and policymakers
- Promoting regulation that supports innovation

**Industry:**

- Medical Device Incubator in partnership with Phillips
- Partner of Venture Capital funds in Israel



**Academia :**

- Drug development and commercialization partner with Israeli academia
- Teva Research Labs at Galilee Medical School
- National network of excellence in neuroscience (NNE) with **15 million dollars investment over the five years**



TEVA

# Thank you!



